Instruction 1(b).

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Tatsis Ourania					2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]										k all app Direc	licable)		rson(s) to Is 10% Ov Other (s	wner
(Last) C/O VEI	(Fir	st) (N	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 08/23/2023									below	v) ``		below) Quality O	ow)
INCORPORATED 50 NORTHERN AVENUE					4. If <i>A</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person					on
(Street) BOSTON MA 02210													Form filed by More than One Reporting Person					orting	
	DOSTOIN IVIA 02210				Rul	Rule 10b5-1(c) Transaction Indication													
(City)	y) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	I - Noı	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	oosed of	or B	enefic	cially	/ Own	ed			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da				Execution E ny/Year) if any		ecution Date,		3. 4. Securitie Transaction Disposed ( Code (Instr. 8) 5)		es Acquired (A Of (D) (Instr. 3,		4 and Securit Benefic Owned		ties cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	(A) (D)	or Prio	e	Reported Transaction (Instr. 3 and				(Instr. 4)		
Common Stock 08/23/2					2023				S <sup>(1)</sup>		2,500	D	\$3	355 4		48,637		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year		4. Transaction Code (Instr. 8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	rities ired r osed ) : 3, 4	Expirati	5. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Dei Sec (Ins	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transactions (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
	Cc		Code	v	(A)	(D)			Expiration Date	Title	or Number of Shares	r							

## **Explanation of Responses:**

 $1.\ Transaction\ made\ pursuant\ to\ Ms.\ Tatsis'\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1,\ which\ was\ entered\ into\ on\ 05/09/2023.$ 

## Remarks:

08/25/2023 /s/ Joy Liu, Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.